What's in Axsome Therapeutics, Inc.'s pipeline?

Axsome Therapeutics, Inc. has 7 drugs in our index: 1 marketed, 0 filed, 6 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Axsome Therapeutics, Inc.'s portfolio?

Top competitors by shared drug class: AUVA Traumazentrum Vienna Site UKH Meidling, Aarhus University Hospital, Amgen, Chinese Society of Lung Cancer, Chinese University of Hong Kong.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/axsome-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Axsome Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Axsome Therapeutics, Inc. pipeline: 1 marketed, 0 filed, 6 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 6 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
AXS-05	AXS-05	marketed	Combination antidepressant (NMDA antagonist + norepinephrine-dopamine reuptake inhibitor)	Sigma-1 receptor, NMDA receptor, norepinephrine transporter, dopamine transporter	Psychiatry/Neurology
AXS-02 (oral zoledronate)	AXS-02 (oral zoledronate)	phase 3	Bisphosphonate	Farnesyl pyrophosphate synthase	Bone metabolism / Oncology
AXS-14 (Esreboxetine)	AXS-14 (Esreboxetine)	phase 3	Norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)	Psychiatry / Neurology
AXS-02	AXS-02	phase 3	NMDA receptor antagonist / Sigma-1 receptor modulator combination	NMDA receptor, Sigma-1 receptor	Neurology / Pain Management
AXS-12 (Reboxetine)	AXS-12 (Reboxetine)	phase 3	Norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)	Psychiatry / Neurology
AXS-07	AXS-07	phase 3	Triptan combination / 5-HT1B/1D receptor agonist	5-HT1B receptor, 5-HT1D receptor	Neurology
AXS-07 (meloxicam-rizatriptan)	AXS-07 (meloxicam-rizatriptan)	phase 3	NSAID + triptan combination	COX-1/COX-2 (meloxicam); 5-HT1B/5-HT1D receptors (rizatriptan)	Neurology

Therapeutic area mix

Neurology · 2
Psychiatry / Neurology · 2
Bone metabolism / Oncology · 1
Neurology / Pain Management · 1
Psychiatry/Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AUVA Traumazentrum Vienna Site UKH Meidling · 1 shared drug class
Aarhus University Hospital · 1 shared drug class
Amgen · 1 shared drug class
Chinese Society of Lung Cancer · 1 shared drug class
Chinese University of Hong Kong · 1 shared drug class
Cttq · 1 shared drug class
Daiichi Sankyo Co., Ltd. · 1 shared drug class
· 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Axsome Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Axsome Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/axsome-therapeutics-inc. Accessed 2026-05-17.